drugset / Trial / NCT01314222

Diabetic Peripheral Neuropathic Pain (DPNP)

NCT01314222

Phase 2 Completed 178 enrolled Bristol-Myers Squibb
RandomizedCrossoverDouble-blindTreatment

Summary

The purpose of the study is to evaluate the efficacy of study drug (BMS-954561) as compared to placebo in the treatment of patients with diabetic peripheral neuropathic pain (DPNP).

Timeline

Start
2011-03
Primary completion
2012-03
Completion
2012-07

Drugs

EvaluationDrugModalityDoseRoute
Subject BMS-954561 Unknown 40 mg
Subject BMS-954561 Unknown 80 mg
Subject BMS-954561 Unknown 150 mg
Subject BMS-954561 Unknown 300 mg
Subject Pregabalin Small molecule 100 mg